Inclusion Criteria:

          -  Patients must have histologically confirmed malignancy that is metastatic or
             unresectable

          -  Cancers with positive BRAF V600 mutation detected by a Clinical Laboratory Improvement
             Act (CLIA)-certified laboratory

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Life expectancy of greater than 3 months

          -  Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1 criteria

          -  Patients must have a K-RAS wild-type (WT) tumor

          -  Absolute neutrophils count >= 1500/mcl (within 14 days)

          -  Platelets >= 100000/mcl (within 14 days)

          -  Hemoglobin (Hb) >= 9 mg/dl (within 14 days)

          -  Total bilirubin =< 1.5 mg/dl (within 14 days)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x upper limit of
             normal if liver metastases present; otherwise, then =< 2.5 x upper limit (within 14
             days)

          -  Estimated creatinine clearance by Cockcroft-Gault equation > 30 mL/min (within 14
             days)

          -  Current treatment may cause harm to the developing human fetus; for this reason women
             of child-bearing age must have a negative pregnancy test at screening and both women
             of child-bearing potential and men must agree to use adequate contraception (hormonal
             or barrier method of birth control; abstinence) prior to study entry and for the
             duration of study participation, and for 6 months after last dose; should a woman
             become pregnant or suspect she is pregnant while she or her partner is participating
             in this study, she should inform her treating physician immediately

          -  Signed informed consent approved by the Institutional Review Board prior to patient
             entry

          -  Expansion cohort: We propose a final expansion cohort for this study in a subset of
             interest utilizing the recommended dosing of combination; this cohort will include
             patients harboring characteristics that may predict response of combination or with
             clinical features that proved to derive most benefit of the study combination during
             preclinical studies; cancers with positive BRAF (V600) mutation detected by a
             CLIA-certified laboratory

        Exclusion Criteria:

          -  Patient receiving any concurrent chemotherapy

          -  Concurrent severe and/or uncontrolled medical disease including, but not limited to,
             ongoing or active infection requiring intravenous antibiotics, bowel obstruction

          -  Symptomatic congestive heart failure (New York Heart Association [NYHA] class III or
             IV), or unstable angina pectoris

          -  Patients who have had a myocardial infarction, transient ischemic attack, unstable
             angina, or cardiovascular symptoms (CVS) within 6 months before treatment

          -  Presence of symptomatic pleural and/or pericardial effusion not appropriately treated

          -  Prolonged corrected QT (QTc) interval (>= 450 msec) as calculated by Bazett's formula,
             or patients with a history of congenital long QT syndrome or uncorrectable electrolyte
             abnormalities

          -  Medical and/or psychiatric problems of sufficient severity to limit full compliance
             with the study or expose patients to undue risk

          -  Known anaphylactic or severe hypersensitivity to the study drugs or their analogs

          -  Patient has failed to recover from any prior surgery within 4 weeks of study entry

          -  Patient is pregnant, lactating, or breastfeeding

          -  Patient has had any treatment specific for tumor control within 3 weeks of dosing with
             investigational drugs and cytotoxic agents, or within 2 weeks of cytotoxic agent given
             weekly, or within 6 weeks of nitrosoureas or mitomycin C, or within 5 half-lives of
             biological targeted agents with half-lives and pharmacodynamic effects lasting less
             than 5 days

          -  Patient is not able to swallow oral medication

          -  Patients receiving any medications or substances that are strong inhibitors or
             inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) complex are
             ineligible

          -  Patients with known K-RAS mutant (codon 12 or 13) detected by a Food and Drug
             Administration (FDA)-approved test in a CLIA-certified laboratory

          -  Patients with BRAF WT cancers